This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Summary: Although mutations in SF3B1 are the most common RNA-splicing factor mutations in cancer, determining the downstream missplicing events that drive tumorigenesis has remained challenging. Liu and colleagues present a model by which mutant SF3B1 tumors displayed high levels of oncogenic MYC activity through the missplicing of PP2A-B56α, a key post-translational regulator of MYC stability, providing a new therapeutic target and driver of SF3B1-mediated tumorigenesis.
See related article by Liu et al., p. 806.
Footnotes
Cancer Discov 2020;10:765–7
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
June 2020
Volume 10, Issue 6
Volume 10, Issue 6
Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis
Jump to section
Advertisement